Exasol Announces Expanded Capabilities of Its Analytics SaaS Database, Including ETL Integration
Exasol, the market leading high-performance analytics database, has announced that from today, Exasol SaaS – the scalable, consumption-based SaaS database based on Amazon Web Services (AWS) – now natively interfaces with Keboola, a cloud-based Data Stack as a Service platform. Keboola provides the first complete solution for data engineers, data analysts, and analytics engineers to deliver on the full spectrum of data demands – from data ingestion to automation. Users will benefit from a built-in function that connects them directly to Keboola from Exasol’s SaaS interface. The Keboola low-code platform provides more than 250 integrations for building ETL/ELT and other pipelines, automation, one-click workflows with integrated business case templates, as well as enterprise grade data governance over the entire stack. It’s a combination that provides improved data accuracy and reduces the time to value.
Commenting on the news, Milan Veverka, VP of Alliances at Keboola said: “We believe that by surrounding ourselves with amazing people, we can achieve anything. That's why we focus on building partnerships that matter. Partnerships with companies that have a similar mindset as we do - empowering everyone to make data-driven decisions. Keboola and Exasol provide great solutions together. We built a simple to use, cost-effective and easy to maintain Data Stack as a Service while Exasol provides its fast in-memory database that helps customers to get to their solution. Together we will make both the implementation and the queries themselves much faster for shared customers.”
In addition to the new collaboration with Keboola, Exasol has introduced a series of new product capabilities that expand on its fully managed, SaaS offering. The new product capabilities will further enhance a customer’s ability to access data-led insights quickly, without needing to manage hardware infrastructures. These innovations include:
- Enhanced AI/ML capabilities: Customers can now solve complex analytics challenges with ease, such as predictive analytics, by bringing in AI/ML algorithms directly to the data. Operationalizing ML models will also bring maximum performance within the database to its users.
- Data virtualization support: Analysts will be able to access objects from external sources without the need for migrating data. This support will also eliminate the need for the costly management of duplicate data. It will allow users to more easily access their data – whether it’s stored locally or in the cloud – and set-up or create a logical data warehouse.
- Amazon SageMaker extension: Exasol SaaS now supports a SageMaker Extension, enabling users to develop end-to-end machine learning projects on data stored in Exasol using the Amazon SageMaker Autopilot service. Doing so mean users can turn data into actionable insights in a matter of minutes.
“When it comes to an organization’s data strategy, data leaders are looking for the confidence to modernize with market-proven, enterprise capabilities that offer flexible migration paths – often to the cloud – at a pace and time that fits with budget and resource constraints,” says Donald Kaye, Chief Commercial Officer at Exasol. The impact of this decision can be profound: affecting costs, the pace of innovation, production releases, marketing penetration and security, to name just a few. “To address the complex challenges organizations face when looking to garner actionable insight from their data, we announced, in February, the strengthening of our hybrid cloud proposition by making our high-performance analytics database available via Exasol SaaS.”
Exasol SaaS is available in two versions. The Exasol SaaS Standard Edition delivers industry leading performance on-demand for organizations with smaller data volumes who don’t require advanced analytics and data integration features or extended support. The Exasol SaaS Enterprise Edition is designed for organizations that require multi-departmental analytics environments, need to perform ML or AI in the database, or have complex requirements in terms of data integration and data virtualization.
Both versions of Exasol SaaS are available here.
About Exasol
Exasol was founded in 2000 with the vision to transform how organizations use data. Today, Exasol’s analytics database – the fastest in the world – is trusted by the world’s most ambitious organizations. With offices in several locations across the US and Europe, Exasol is committed to delivering flexible, scalable and powerful analytics solutions to customers wherever they are, in the cloud – public or private - or on-premises.
Exasol – the leading Performance Analytics Database powering insights from the world’s data.
Learn more at: www.exasol.com and follow us on social media: LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005032/en/
Contact information
Isabella Alder, EMEA PR Manager at Exasol
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
